FDA approves “glowing tumour” imaging drug to aid lung cancer surgery
The U.S. Food and Drug Administration (FDA) has approved the targeted imaging agent pafolacianine for use in…
Browsing: FDA Approvals
FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer
On December 16, 2022, the Food and Drug Administration approved nadofaragene firadenovec-vncg for adult patients with…
FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer
The Food and Drug Administration granted accelerated approval to mirvetuximab soravtansine-gynx for adult patients with folate…
FDA approves cemiplimab-rwlc in combination with platinum-based chemotherapy for non-small cell lung cancer
The Food and Drug Administration approved cemiplimab-rwlc in combination with platinum-based chemotherapy for adult patients with…
FDA approves brentuximab vedotin in combination with chemotherapy for paediatric patients with classical Hodgkin lymphoma
The Food and Drug Administration approved brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone, and…
FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer
On August 11, 2022, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki for…
FDA approves capmatinib for metastatic non-small cell lung cancer
On August 10, 2022, the Food and Drug Administration granted regular approval to capmatinib for adult…
FDA approves darolutamide tablets for metastatic hormone-sensitive prostate cancer
On August 5, 2022, the Food and Drug Administration approved darolutamide tablets in combination with docetaxel…
FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer
On August 5, 2022, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki for adult patients…
FDA approves lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer
The Food and Drug Administration have approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for the…